Yeah, my AI detector saw it in Jouni’s eyes in the interview that OCT will be in Reve’s portfolio within the current year : )
Juha’s extensive report stated just over a year ago:
“In our view, the most obvious area for expanding Revenio’s device offering is Optical Coherence Tomography (OCT), which belongs to the imaging market. This accounts for about 500 MEUR of the roughly 1.3 billion dollar imaging market, and Revenio currently has no offering in this segment. We expect Revenio to grow into this area in the medium term either through its own product development (extremely challenging) or through an acquisition (valuation levels are high). Expansion through an acquisition could even be rapid if the pieces fall into place.”
Gemini gave an even bolder estimate:
“The global size of the ophthalmology optical coherence tomography (OCT) market is estimated to be in 2026 approximately 1.61 – 2.19 billion dollars. Ophthalmology applications make up the largest part of the total OCT device market, and their share is estimated at approximately 69.2 %”
In light of these figures, it’s pretty clear that Reve should get a device too, especially since the OCT market’s share of the whole pie also seems to be in strong growth.
Exciting year ahead. Apparently, those ongoing US customs etc. messes have weighed on the valuations of Reve and Opto as well. Both still have fairly decent growth figures.